-transparent.png){kind=logo}
In five conscious dogs we studied the effect of proglumide, a cholecystokinin (CCK) antagonist, on caerulein-stimulated pancreatic secretion and release of pancreatic polypeptide (PP). Graded doses of caerulein (15-240 ng/kg per h) were infused intravenously. Experiments were repeated with a fixed infusion of proglumide (40 mg/kg per h). Release of PP following increasing doses of caerulein was significantly inhibited by proglumide (P less than 0.01). However, proglumide did not significantly affect caerulein-stimulated pancreatic protein secretion. Proglumide might be useful in defining the physiological role of CCK.
Related Publications
M Fried, and
C Beglinger, and
E Koehler, and
I Whitehouse, and
L Varga, and
K Gyr
September 1990,
Surgery,
M Fried, and
C Beglinger, and
E Koehler, and
I Whitehouse, and
L Varga, and
K Gyr
February 1991,
Gut,
M Fried, and
C Beglinger, and
E Koehler, and
I Whitehouse, and
L Varga, and
K Gyr
February 1991,
Regulatory peptides,
M Fried, and
C Beglinger, and
E Koehler, and
I Whitehouse, and
L Varga, and
K Gyr
May 1991,
The Journal of clinical endocrinology and metabolism,
M Fried, and
C Beglinger, and
E Koehler, and
I Whitehouse, and
L Varga, and
K Gyr
December 1990,
Gastroenterology,
M Fried, and
C Beglinger, and
E Koehler, and
I Whitehouse, and
L Varga, and
K Gyr
March 1986,
Naunyn-Schmiedeberg's archives of pharmacology,
M Fried, and
C Beglinger, and
E Koehler, and
I Whitehouse, and
L Varga, and
K Gyr
February 1984,
Gastroenterologia Japonica,
M Fried, and
C Beglinger, and
E Koehler, and
I Whitehouse, and
L Varga, and
K Gyr
September 1994,
Journal of surgical oncology,
M Fried, and
C Beglinger, and
E Koehler, and
I Whitehouse, and
L Varga, and
K Gyr
January 1984,
American journal of surgery,
M Fried, and
C Beglinger, and
E Koehler, and
I Whitehouse, and
L Varga, and
K Gyr
December 1989,
Regulatory peptides,
